All told, it looks like LLY's Retatrutide—(and similar drugs such as Hanmi's HM15211)—will have a narrow therapeutic window, if there is any window at all.
LLY is a hot stock, and investors are acting as though it can do no wrong. Several mainstream news sources have (perhaps unintentionally) downplayed the safety issues of some of the weight-loss drugs.
Market Data 
Markets 
AI
